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ABSTRACT
Humanmyxovirus resistance 2 (MX2/MXB) is an interferon-stimulated gene (ISG) and was recently identified as a late postentry
suppressor of human immunodeficiency virus type 1 (HIV-1) infection, inhibiting the nuclear accumulation of viral cDNAs. Al-
though the HIV-1 capsid (CA) protein is believed to be the viral determinant of MX2-mediated inhibition, the precise mecha-
nism of antiviral action remains unclear. TheMX family of dynamin-like GTPases also includes MX1/MXA, a well-studied in-
hibitor of a range of RNA and DNA viruses, including influenza A virus (FLUAV) and hepatitis B virus but not retroviruses. MX1
andMX2 are closely related and share similar domain architectures and structures. However, MX2 possesses an extended N ter-
minus that is essential for antiviral function and confers anti-HIV-1 activity onMX1 [MX1(NMX2)]. Higher-order oligomeriza-
tion is required for the antiviral activity of MX1 against FLUAV, with current models proposing that MX1 forms ring structures
that constrict around viral nucleoprotein complexes. Here, we performed structure-function studies to investigate the require-
ments for oligomerization of bothMX2 and chimeric MX1(NMX2) for the inhibition of HIV-1 infection. The oligomerization
state of mutated proteins with amino acid substitutions at multiple putative oligomerization interfaces was assessed using a
combination of covalent cross-linking and coimmunoprecipitation. We show that while monomeric MX2 andMX1(NMX2) mu-
tants are not antiviral, higher-order oligomerization does not appear to be required for full antiviral activity of either protein.
We propose that lower-order oligomerization of MX2 is sufficient for the effective inhibition of HIV-1.
IMPORTANCE
Interferon plays an important role in the control of virus replication during acute infection in vivo. Recently, cultured cell exper-
iments identified humanMX2 as a key effector in the interferon-mediated postentry block to HIV-1 infection. MX2 is a member
of a family of large dynamin-like GTPases that includes MX1/MXA, a closely related interferon-inducible inhibitor of several
viruses, including FLUAV, but not HIV-1. MXGTPases form higher-order oligomeric structures, and the oligomerization of
MX1 is required for inhibitory activity against many of its viral targets. Through structure-function studies, we report that mo-
nomeric mutants of MX2 do not inhibit HIV-1. However, in contrast to MX1, oligomerization beyond dimer assembly does not
seem to be required for the antiviral activity of MX2, implying that fundamental differences exist between the antiviral mecha-
nisms employed by these closely related proteins.
Type 1 interferons (IFNs) are key cytokine mediators of innateimmunity and promote an antiviral state in response to acute
viral infection through the upregulation of interferon-stimulated
genes (ISGs) (1, 2). Human myxovirus resistance 2 (MX2/MXB)
recently has been identified as an interferon-inducible late posten-
try inhibitor of human immunodeficiency virus type 1 (HIV-1)
infection (3–5). MX2 imposes a block to viral replication that
occurs after reverse transcription but prior to nuclear import, pre-
venting the accumulation of nascent viral cDNAs in the nucleus
(3, 4). The HIV-1 capsid (CA) protein is believed to be the viral
determinant of inhibition (3–5); indeed, MX2 has been shown to
interact with recombinant capsid-nucleocapsid nanotubes in
vitro. However, the precise mechanism of antiviral action remains
unclear, not least because point mutations in CA that permit viral
escape fromMX2-mediated suppression do not appear to inhibit
binding of MX2 (6–8).
Human MX2 is a member of a family of large dynamin-like
GTPases that includes human MX1/MXA, a long-established in-
terferon-induced inhibitor of a broad range of RNA and DNA
viruses (9). Viruses inhibited by MX1 include influenza A virus
(FLUAV), La Crosse virus, Thogoto virus, measles virus, and hep-
atitis B virus but not retroviruses such as HIV-1 (3, 9). While the
precise mechanism of action may differ for different viruses,
GTPase activity and oligomerization are required for antiviral
activity of MX1 against FLUAV, the prototypical target of MX1
restriction (10–12). Current models propose that MX1 forms oli-
gomeric rings that interact with viral nucleoprotein complexes
(13–15) and constrict around their target uponGTPhydrolysis (9,
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16, 17). In contrast, GTPase activity is not essential forMX2 func-
tion (3, 4, 18, 19), and the importance of oligomerization beyond
dimer formation for antiviral activity has been questioned (6, 20),
pointing to substantial differences in mechanisms of action.
HumanMX1andMX2share63%sequence identity and the same
domain architecture, and the structures of the two proteins are very
similar, with a root-mean-square deviation of 6.4 Å for backbone
atoms(6, 16, 21).Bothproteins comprise anamino-terminalGTPase
domain (G domain) and a carboxy-terminal stalk domain that are
connected by a tripartite bundle signaling element (BSE) (Fig. 1).
Comprehensive structural and biochemical studies with MX1 have
shown that the stalk domain is critical for oligomerization (10, 17),
while the BSE transmits conformational changes between the G do-
main and stalk upon GTP binding and hydrolysis (16).
MX2 possesses an extended N terminus compared to that of
MX1; indeed, this region has been shown to be essential for anti-
HIV-1 activity (22, 23). MX2 also exists as two isoforms (24) due
to the presence of an alternative initiation methionine codon at
position 26. The longer 78-kDa form is antiviral and is partly
associated with the nuclear envelope, while the shorter 76-kDa
isoform is not antiviral and is cytoplasmic owing to the absence
of a nuclear envelope targeting sequence. The precise role of
the MX2 N-terminal region presently is unclear, but it does
contain essential functional determinants other than a nuclear
envelope targeting sequence (22, 23, 25). More specifically, a
triple-arginine motif at positions 11 to 13 is required for
anti-HIV-1 activity (20) and recently has been proposed as an
HIV-1 CA binding motif (26). Furthermore, the N-terminal 91
amino acids of MX2 are sufficient to confer anti-HIV-1 activity on
MX1 [MX1(NMX2)] and, remarkably, on heterologous protein scaf-
FIG1 Structure and predicted oligomerization interfaces of humanMX2. (A)Crystal structure of theMX2 dimer (protomers in green and blue) fromFribourgh
et al. (6) (PDB entry 4WHJ), in cartoon representation. The G domain, bundle signaling element (BSE), hinge region, stalk domain, and L1, L2, and L4 loops are
indicated. The dimer interface (interface 2) between stalk domains is also shown (dashed line). (B) Predicted oligomerization interfaces ofMX2. A dimer of stalk
dimers (green and blue; purple and orange) is shown with dimer interface 2 and putative oligomerization interfaces 1 and 3 indicated. The latter two interfaces
correspond to crystallographic symmetry-related interfaces. Residues predicted to stabilize each interface by homology to MX1 are shown as sticks. All figures
were generated using the PyMol Molecular Graphics System (Schrödinger).
MX2 Oligomerization
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folds (20, 22, 23, 25). Importantly, chimeric MX1(NMX2) recapitu-
latesmany features and specificities ofMX2-mediated antiviral activ-
ity (23); therefore, it serves as a valuable tool in dissecting its
mechanism of action.
Here, we performed site-directedmutagenesis studies to inves-
tigate in detail the importance of oligomerization for the inhibi-
tion ofHIV-1 infection in the context of both humanMX2 and the
MX1(NMX2) chimera. Basing our work on previous studies per-
formed with MX1 and FLUAV (10, 16) and recently published
structural data for an amino-terminally truncated form of MX2
(6), we generated a series of point mutants at the various oli-
gomerization interfaces within the stalk domain and determined
their anti-HIV-1 activity (Table 1). Protein cross-linking and co-
immunoprecipitation assays were used to assess the oligomeriza-
tion state of themutant proteins.We show thatmonomeric forms
ofMX2 andMX1(NMX2) lack antiviral function, but in contrast to
MX1 inhibition of FLUAV, oligomerization beyond dimer assem-
bly does not appear to be required for anti-HIV-1 activity.
MATERIALS AND METHODS
Cell culture and plasmid constructs. Human 293T cells and U87-MG
CD4 CXCR4 (3) cells were cultured in Dulbecco’s modified Eagle me-
dium (DMEM) supplemented with fetal bovine serum (10%), L-glu-
tamine, and penicillin-streptomycin. Site-directed mutagenesis was per-
formed on human MX2 or MX1(NMX2) (residues 1 to 91 of MX2
appended to residues 44 to 662 of human MX1 [23]) constructs contain-
ing a C-terminal FLAG tag using standard PCR amplification techniques.
For the loop 4 (L4) deletionmutants, overlapping PCR was used to delete
residues 580 to 608 of MX2, and the sequence corresponding to residues
533 to 561 of native human MX1 (10) was deleted in the context of the
MX1(NMX2) chimera. Mutant constructs were cloned into EasiLV-MCS
(3) using BamHI and XhoI restriction sites. FLAG-tagged mutants then
were subcloned into pCAGGS (Addgene) using BclI and XhoI restriction
sites.GFP,MX1, andMX2were subcloned into pCMV4.HA using Acc65I
and XbaI to introduce a triple-hemagglutinin (HA) tag at the C terminus
before further subcloning into EasiLV-MCS or pCAGGS. AnMX1(NMX2)
construct with a C-terminal triple-HA tag was generated by overlapping
PCR using HA-taggedMX1 as a template and cloned into pCAGGS using
NotI and XhoI restriction sites.
HIV-1 vector infectivity assays. HIV-1 infectivity assays were per-
formed as described previously (3, 20, 23). Briefly,U87-MGCD4CXCR4
cells were transduced with C-terminally FLAG-tagged CD8, MX1, MX2, or
MX1(NMX2) gene constructs using the doxycycline-inducible EasiLV lentivi-
ral vector system (3). After 6 h, transgene expression was induced for72 h
prior to challengeby the additionofdoxycycline [0.05g/ml forMX1(NMX2)
constructs, 0.5g/ml for all other constructs]. EasiLV transduction efficiency
typicallywas above85%andwasassessedbymeasuring thepercentageof cells
expressing E2-crimson (coexpressed via an internal ribosome entry site
[IRES]) by flow cytometry (FACSCanto II; BD Biosciences). Protein expres-
sion was assessed by immunoblotting; cell pellets were lysed in sample buffer
(200 mM Tris-HCl, pH 6.8, 5.2% SDS, 20% glycerol, 0.1% bromophenol
blue, 5% -mercaptoethanol), resolved by SDS-PAGE, and analyzed using
anti-FLAG(mousemonoclonalM2; Sigma-Aldrich) and anti-Hsp90 (rabbit;
SantaCruzBiotechnology) antibodiesbychemiluminescence. Forviral infec-
tion,2.5 104 to 5 104 cells were seeded in 96-well plates and challenged
with a vesicular stomatitis virusG protein (VSVG)-pseudotyped 8.91HIV-1
Gag-Pol-based cytomegalovirus (CMV) immediate early-enhanced green
fluorescent protein lentiviral vector (HIV-1/GFP) at a multiplicity of infec-
tion (MOI)of 0.2. Productive infectionwas enumeratedbyflowcytometry as
the percentage of E2-crimson-positive cells expressing GFP at48 h postin-
fection by flow cytometry. EasiLV particles and challenge HIV-1/GFP vector
stocks were prepared as described previously (3, 23).
Protein cross-linking.U87-MG CD4 CXCR4 cells (3) were trans-
duced in 6-well plates with EasiLV vectors carrying MX1, MX2, or
MX1(NMX2) FLAG-tagged constructs, and expression was induced with
doxycycline as described previously. After72 h, cells were harvested in
phosphate-buffered saline (PBS; Life Technologies), and cell pellets were
resuspended in cell lysis buffer (1 PBS, 0.5% Triton X-100, 1 protease
inhibitor cocktail [Roche]) and lysed by brief sonication. Lysate was
cleared by centrifugation at 1,500  g for 10 min. The covalent cross-
linking agent disuccinimidyl suberate (DSS; Thermo Scientific), a non-
cleavable, amine-reactive N-hydroxysuccinimide (NHS) ester, was dis-
solved in dimethyl sulfoxide (DMSO) at a stock solution of 10mg/ml and
added to cell lysates at a final concentration of 100 g/ml or 25 g/ml.
Samples containing 1% DMSO only were included as a control. Cross-
linking reaction mixtures were incubated at room temperature for 1 h
before the addition of protein sample buffer and resolved by SDS-PAGE
on a 6% acrylamide gel. Immunoblotting was performed using a horse-
radish peroxidase (HRP)-conjugated anti-FLAG antibody (mousemono-
clonal M2; Sigma-Aldrich) and chemiluminescence.
For cross-linking followed by immunoprecipitation, 293T cells were
cotransfected with pCAGGS carrying FLAG-taggedMX2 orMX1(NMX2)
andpCAGGS carrying triple-HA-taggedMX2orMX1(NMX2) usingTran-
sIT-2020 reagent (Mirus). After 30 h, cells were harvested and DSS
cross-linking performed as described previously. After 1 h, cross-linker
was quenched with 50mMTris-HCl for 15min, and cross-linked protein
was immunoprecipitated in modified radioimmunoprecipitation assay
(RIPA) buffer (50mMTris-HCl, pH7.6, 150mMNaCl, 1%TritonX-100,
TABLE 1 Summary of oligomerization mutants used in this studya
MX1 mutant Region
MX1
oligomerization
MX1 antiviral
activityb (FLUAV)
Corresponding
MX2 mutation
WT Tetramer Yes
L617D Stalk interface 1 Dimer No M666D
I376D Stalk interface 1 Dimer — I423D
M527D Stalk interface 2 Monomer No M574D
F602D Stalk interface 2 Monomer — Y651D
YRGR440-AAAA443 Stalk interface 3 Dimer — YRGK487-AAAA490
R408D Stalk interface 3 Dimer No R455D
G392D Stalk interface 3 Dimer — G439D
E632A BSE hinge Dimer Partial E681A
R640A BSE hinge Dimer No R689A
L4 L4 loop Dimer No L4
a Shown is an overview of mutations previously shown to disrupt MX1 oligomerization (10, 16), their location within MX1, oligomerization state in sedimentation equilibrium
assays with recombinant protein (10, 16), and consequences for anti-FLUAV activity (10, 16). Mutations generated in MX2 for this study, corresponding to those previously
characterized for MX1, are shown. The same MX1 mutations shown here also were introduced in the context of the MX1(NMX2) chimera in this study.
b A dash indicates that the anti-FLUAV activity of the respective mutant was not tested.
Dicks et al.
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1% sodium deoxycholate, 0.5% SDS) using anti-HA magnetic beads
(Pierce) for 2 h at 4°C. Beadswerewashed 4 times inmodifiedRIPAbuffer
with the NaCl concentration raised to 500 mM prior to the addition of
sample buffer, resolution by SDS-PAGE, and detection of HA- or FLAG-
tagged MX2 or MX1(NMX2) by immunoblotting using HRP-conjugated
anti-HA (rat monoclonal 3F10; Sigma-Aldrich) or anti-FLAG antibodies.
Coimmunoprecipitation. 293T cells were seeded in 6-well plates and
cotransfected with pCMV4- and pCAGGS-based plasmids encoding tri-
ple HA-tagged and FLAG-tagged constructs, respectively, using polyeth-
ylenimine. After 30 h, cells were harvested, resuspended in hypotonic
lysis buffer (10 mMTris-HCl, pH 8.0, 10 mMKCl, 1 protease inhibitor
cocktail [Roche]), and lysed by Dounce homogenization. Lysates were
cleared by centrifugation at 1,500  g for 10 min, and KCl and Triton
X-100were added to cleared lysates at final concentrations of 100mMand
0.3%, respectively. HA-tagged proteins were immunoprecipitated using
anti-HA magnetic beads (Pierce) for 2 h at 4°C, and beads were washed a
further 4 times in wash buffer (10 mM Tris-HCl, pH 8.0, 200 mM KCl,
0.3%Triton X-100) before the addition of sample buffer. HA- and FLAG-
tagged proteins were resolved on 10% acrylamide gels by SDS-PAGE and
detected by immunoblotting using HRP-conjugated anti-HA or anti-
FLAG antibody.
RESULTS
Importance of the stalk oligomerization interfaces, BSE hinge
region, and L4 loop for the antiviral activity ofMX2. The crystal
structure of the human MX2 dimer (residues 84 to 715) is shown
in Fig. 1A (6). Human MX2 previously has been shown to form
higher-order oligomers (27), and oligomerization via the stalk
domain has been predicted to proceed in a manner similar to that
of themodel described for humanMX1 (10). Figure 1B shows two
crystallographic symmetry-related MX2 stalk dimers, highlight-
ing the interaction interface involved in dimerization (interface 2)
and putative higher-order oligomerization interfaces (interfaces 1
and 3) corresponding to those described and characterized in de-
tail forMX1 (10) and the related GTPase dynamin (28). ForMX1,
the dimer has been proposed as the basic structural unit (10),
with interfaces 1 and 3 enabling tetramerization and subse-
quent formation of the higher-order ring structures that have
been observed in vitro (13). Recombinantly expressed wild-
type MX1 forms stable tetramers in solution, while proteins
with mutations in stalk interface 1 or 3 are dimeric, and pro-
teins with mutations in interface 2 are monomeric (10) (Table
1). Mutation at the BSE hinge region of MX1 (E632A and
R640A) and deletion of the L4 loop (which acts as a viral spec-
ificity determinant in the context of MX1 [29, 30]) also disrupt
MX1 tetramer formation (10, 16). Importantly, disruption at
each of these interfaces led to the abrogation of MX1’s anti-
FLUAV activity (10, 16) (Table 1).
In the current study, mutations corresponding to those char-
acterized previously for MX1 (10, 16) were generated at the pre-
dicted stalk interfaces, BSE hinge region, and L4 loop of MX2, as
outlined in Table 1. The locations of targeted residues within the
MX2 stalk are shown in Fig. 1B. Putative dimer interface residues
V578 and F647 were identified from the MX2 crystal structure
alone (6). The MX2 L2 loop mutation YRGK487-AAAA490, corre-
sponding to YRGR440-AAAA443 inMX1, facilitated crystallization
of both proteins (6, 10) and previously has been shown to disrupt
stalk interface 3 in the context of MX1 (10).
The ability of these MX2 stalk mutants to inhibit HIV-1 infec-
tionwas tested (Fig. 2).Wild-type andmutated FLAG-tagged con-
structs were expressed in U87-MGCD4CXCR4 cells using the
doxycycline-inducible EasiLV lentiviral vector system (3), as con-
firmed by immunoblot analysis of cell lysates (Fig. 2, lower).
Transduced cells subsequently were challenged with an HIV-1-
based lentiviral vector (HIV-1/GFP), and transduction effi-
ciency was assessed 48 h postchallenge by flow cytometry. In
agreement with previous studies, wild-type humanMX2 inhib-
ited HIV-1 infection by90% relative to that of the CD8 neg-
ative control, whereas the sole expression of the MX226–715
short isoform had no antiviral effect (Fig. 2, upper) (3, 20, 23).
Dimer interface mutants M574D, Y651D, and F647D all exhib-
ited an essentially complete loss of antiviral activity, while
V578D exhibited a partial loss of activity (80% inhibition
relative to that of the CD8-negative control). Mutations at stalk
interface 1 (M666D and I423D) had no effect on antiviral ac-
tivity (90% inhibition), whereas mutations at interface 3
yielded variable results, with R455D retaining modest activity
(50% inhibition) but YRGK487-AAAA490 and G439D both
retaining full activity. BSE-stalk hinge region mutants E681A
and R689A also exhibited a significant reduction in antiviral
activity (55 to 65% inhibition), and deletion of the L4 loop
moderately affected function (L4; 80% inhibition). The
dimer interface mutants M574D, Y651D, and F647D were con-
sistently expressed at slightly lower levels than V578D (Fig. 2,
lower), perhaps contributing to the severity of the impairment
to antiviral activity observed for these mutants. However, all
FIG 2 Mutations at the dimer interface, oligomerization interface 3, and hinge
region impair anti-HIV-1 activity of MX2. (Upper) U87-MG CD4 CXCR4
cells were transducedwith EasiLVvectors expressing FLAG-taggedCD8 (negative
control), MX226–715 (Short), wild-typeMX2 (WT), or a series ofMX2 constructs
that were mutated at predicted stalk oligomerization interfaces 1, 2, and 3 or the
BSE-hinge (H) regionor thatwere deleted of the L4 loop (L4). Cellswere treated
with doxycycline (0.5 g/ml) for72 h prior to challenge with an HIV-1-based
lentiviral vector expressing GFP (HIV-1/GFP) at an MOI of 0.2. After 48 h
postchallenge,HIV-1/GFPtransductionefficiencywasassessedbyflowcytometry.
Mean percentages of transduced cells from three independent experiments with
standard deviations are shown. (Lower) Immunoblot analysis of parallel samples
from the upper panel. Levels of FLAG-tagged proteins were determined, and
Hsp90 was included as a loading control.
MX2 Oligomerization
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other mutant proteins tested exhibited similar or higher ex-
pression levels than wild-type MX2.
Characterizing the oligomerization state of MX2 stalk mu-
tants. To investigate further the relationship between MX2 oli-
gomerization and antiviral activity, the oligomerization states
of MX2 stalk mutants were addressed. Chemical cross-linking
of protein from mammalian cell extracts with disuccinimidyl
suberate (DSS), a noncleavable, amine-reactive N-hydroxysuc-
cinimide (NHS) ester, enabled the identification of lower-or-
der and higher-order oligomers for wild-type MX1 and MX2,
chimeric MX1(NMX2), and the MX2 stalk variants (Fig. 3).
U87-MG CD4 CXCR4 cells were transduced with EasiLV vec-
tors expressing FLAG-tagged constructs, and expression was
induced with doxycycline. DSS cross-linking of cell lysates re-
FIG 3 Chemical cross-linking reveals oligomerization state of MX2 stalk mutants. (A) U87-MG CD4 CXCR4 cells were transduced with EasiLV vectors
expressing FLAG-tagged MX1, MX2, or MX1(NMX2), and protein expression was induced by the addition of doxycycline for72 h. Cells were harvested and
lysed, and disuccinimidyl suberate (DSS) was added to lysates at a concentration of 25 or 100g/ml (0 indicates DMSO-only control). After 1 h the reaction was
quenched, and FLAG-tagged protein was resolved by SDS-PAGE and detected by immunoblotting. (B) Cross-linking followed by immunoprecipitation. 293T
cells were cotransfected with FLAG-tagged MX2 WT or MX1(NMX2) WT and HA-tagged MX2 WT or MX1(NMX2) WT. After30 h cells were lysed, protein
cross-linked with DSS, andHA-tagged protein immunoprecipitated with anti-HA antibody. Cells transfected with FLAG-tagged constructs alone were included
as a negative control. Immunoblots of immunoprecipitated protein were probed with both anti-HA and anti-FLAG antibodies. (C) Cross-linking profiles of
FLAG-taggedMX2 stalkmutants. U87-MGCD4CXCR4 cells were transduced, the expression of FLAG-tagged constructs was induced, andDSS cross-linking
was performed as described for panel A. FLAG-tagged protein was resolved by SDS-PAGE and detected by immunoblotting. MX2 WT was included on each
membrane to enable the direct comparison of the mutants to the wild type. The HIV-1 inhibition phenotype of each mutant from Fig. 2 is indicated (calculated
as percent inhibition relative to that of the CD8 control);	,
50%;, 50 to 85%;,85%.
Dicks et al.
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vealed a similar concentration-dependent distribution of lower-
and higher-order oligomers for MX1, MX2, and MX1(NMX2)
(Fig. 3A). Monomeric proteins were observed at 80-kDa (76-
kDa MX1 and 78-kDa and 76-kDa MX2 isoforms), with further
speciesmigration between the 136-kDa and 190-kDamarkers cor-
responding to lower-order oligomers. The approximate molecu-
lar masses of these species are broadly consistent with those of
dimers and trimers, respectively, although this has not been formally
proven. The presence of more than two discrete species within this
region of the gel indicates the presence of additional cross-linked (as
yet unidentified) MX binding partners. Discrete high-molecular-
mass bands most likely corresponding to tetramers and/or higher-
order oligomers also can be identified for MX1, MX2, and
MX1(NMX2),with an increase in abundanceof these species observed
with the higher DSS concentration (Fig. 3A).
As a control to confirm that slower-migrating cross-linked com-
plexes represented adducts containing multiple MX protein mole-
cules rather than complexes with other cellular proteins, FLAG-
tagged and HA-tagged wild-type MX2 or chimeric MX1(NMX2)
were coexpressed in 293T cells (data not shown), lysates cross-
linked, and HA-tagged protein immunoprecipitated (Fig. 3B). As
shown by subsequent immunoblotting, complexes containing
FLAG-taggedMX proteins were readily isolated with the HA-spe-
cific antibody, comparable distributions of the higher-molecular-
mass cross-linked species were observed when probing for HA- or
FLAG-tagged proteins, and the banding patterns were similar to
that observed previously (Fig. 3A). Together, these data show that
our cross-linking approach measures the oligomerization of MX
proteins, as opposed to the formation of complexes with addi-
tional cellular proteins.
MX2 stalk mutants varied considerably in their ability to oli-
gomerize (Fig. 3C), but in general lower-order oligomer forma-
tion corresponded with antiviral activity. Dimer interface (inter-
face 2) mutants M574D, Y651D, and F647D lost the ability to
form oligomers, with monomeric protein being the only species
detected in this assay. This result is consistent with these residues
being important for maintaining the dimer interface, supporting
recent structural studies (6). Importantly, each of these three mu-
tants exhibited a complete loss of antiviral activity (Fig. 2). V578D,
also located at the predicted dimer interface, formed lower-order
oligomers inefficiently with undetectable higher-order oligomer-
ization (Fig. 3C) and had partial antiviral activity (Fig. 2).
In contrast, stalk interface 1 mutants M666D and I423D did
not affect MX2 oligomerization, with a distribution and abun-
dance of lower- and higher-order oligomeric species comparable
to that of wild-type MX2 (Fig. 3C). These data call into question
the physiological relevance of predicted stalk interface 1, and cer-
tainly these residues are not required either for oligomerization or
the antiviral activity of MX2 (Fig. 2). Stalk interface 3 mutant
G439D had no oligomerization defect, while L2 loop mutant
YRGK487-AAAA490 formed lower-order oligomers but exhibited
significantly impaired higher-order oligomerization (Fig. 3C).
Both mutants, however, retained full anti-HIV-1 activity (Fig. 2).
R455D, however, exhibited barely detectable lower-order oli-
gomerization, no detectable higher-order oligomerization (Fig.
3C), and significantly reduced antiviral activity (Fig. 2). The BSE
hinge regionmutants E681A andR689A both formed lower-order
and higher-order oligomers, albeit at reduced abundance com-
pared to that of wild-type MX2 (Fig. 3C). Interestingly, both mu-
tants demonstrated onlymodest antiviral activity (Fig. 2), perhaps
due to the reduction in overall efficiency of oligomerization. De-
letion of the L4 loop also incurred a significant oligomerization
defect, with lower-order species barely being detected. Taken to-
gether, the infectivity and cross-linking data presented thus far
imply a strict requirement for efficient lower-order oligomeriza-
tion for full antiviral activity of MX2.
To validate our observations regarding oligomerization of
MX2 via an alternative approach, coimmunoprecipitation studies
were performed with HA-tagged wild-type MX2 and FLAG-
tagged MX2 stalk mutants expressed in 293T cells, HA-specific
immunoprecipitation, and detection of associated FLAG-tagged
proteins (Fig. 4). The assessment of coimmunoprecipitation effi-
ciency between wild-type and mutant proteins parallels the ap-
proach previously used in the context of MX1 (10). HA-tagged
GFP was included as a negative control, and HA-tagged wild-type
MX1 also was included, since MX1 and MX2 do not significantly
colocalize and are not believed to form hetero-oligomers (27). All
HA-tagged and FLAG-tagged constructs were well expressed (Fig. 4,
lower), andHA-taggedproteinswere efficiently immunoprecipitated
in all samples (Fig. 4, upper). As expected, FLAG-tagged wild-type
MX2 was efficiently coimmunoprecipitated with HA-tagged wild-
type MX2 but not with the GFP-HA control, and only a very weak
interaction was observed betweenMX1 andMX2 (Fig. 4, upper).
In concordance with our cross-linking data, dimer interface
mutants M574D, Y651D, and F647D exhibited only very weak
interactions with wild-type MX2 (comparable to that observed
between MX1 and MX2), while stronger interactions were ob-
served with V578D. BSE hinge mutants E681A and R689A and
stalk interface 3 mutant R455D, all of which showed reduced an-
tiviral activity (Fig. 2), exhibited weak coimmunoprecipitation
withwild-typeMX2 (Fig. 4). Stalk interface 1mutantsM666Dand
I423D and interface 3 mutant G392D coprecipitated with an effi-
FIG 4 Coimmunoprecipitation of MX2 stalk mutants with wild-type MX2.
293T cells were cotransfected with HA-tagged MX2 WT and FLAG-tagged
MX2WT or stalk mutants. Cells were lysed and HA-tagged protein immuno-
precipitated with anti-HA antibody. The cotransfection of HA-tagged GFP or
MX1 with FLAG-tagged MX2 WT also were included as negative controls.
(Upper) Immunoblots of immunoprecipitated protein (IP) were probed with
anti-FLAG or anti-HA antibodies. (Lower) Immunoblots of cell lysate prior to
immunoprecipitation (INPUT) were probed with anti-FLAG or anti-HA an-
tibody as a control for protein expression.
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ciency comparable to that of wild-type MX2, again correlating
with the cross-linking data and their full antiviral activity (Fig. 2).
The L2 loop mutant YRGK487-AAAA490 also exhibited efficient
coimmunoprecipitation (Fig. 4) despite a clear defect in higher-
order oligomerization (Fig. 3). Since YRGK487-AAAA490 also re-
tained full antiviral activity, this result implies that higher-order
oligomerization is dispensable for MX2 function, provided that
lower-order oligomerization is sufficiently robust.
The dimer interface is important for anti-HIV-1 activity of
MX1(NMX2).We next sought to determine whether oligomeriza-
tion also is required for the anti-HIV-1 activity of chimeric
MX1(NMX2).MX1(NMX2), a fusion of residues 1 to 91 ofMX2 and
44 to 662 of MX1, which therefore replaces the native N terminus
of MX1 with the extended N-terminal region of MX2, can inhibit
HIV-1 with potency comparable to that of wild-type MX2 (23).
MX1(NMX2) recapitulates many of the features associated with
MX2-mediated inhibition: infection is blocked prior to nuclear
cDNA import, GTPase activity is dispensable for function, and
viral substrate specificity is comparable (23). In this study, the
biochemical characterization of mutated proteins carrying previ-
ously described MX1 oligomerization deficiencies (10, 16) was
exploited to investigate the role ofMX1(NMX2) oligomerization in
anti-HIV-1 activity. Mutations in the stalk region, BSE hinge re-
gion, and L4 loop previously shown to disrupt MX1 oligomeriza-
tion (Table 1) were introduced in the context of chimeric
MX1(NMX2). Note that, for ease of reference to previous studies,
residue numbers assigned to these mutants represent the position
in the native MX1 sequence.
The ability of FLAG-tagged mutant constructs to inhibit HIV-
1/GFP vector infection was tested and compared to that of wild-
typeMX1(NMX2) in a series of experiments performed in the same
way as those described for Fig. 2. All FLAG-tagged constructs were
well expressed in cell lysates (Fig. 5, lower). Note that chimeric
MX1(NMX2) also exists as two isoforms due to the alternative ini-
tiation codon within the N terminus of MX2. As previously de-
scribed (3, 23), MX1(NMX2) expression inhibited HIV-1 transduc-
tion by over 90%, at least equivalent to the inhibition conferred by
MX2, while MX1 had no antiviral activity against HIV-1 (Fig. 5, up-
per). Strikingly, the onlymutant protein that incurred any significant
reduction in antiviral activity was the dimer interface mutant
M527D, which exhibited a complete loss of activity.
Characterizing the oligomerization state of MX1(NMX2)
stalk mutants. The oligomerization state of FLAG-tagged
MX1(NMX2) stalk mutants was assessed by protein cross-linking
as shown in Fig. 3. The dimer interface mutant M527D, the only
MX1(NMX2) stalk mutant analyzed here to lose antiviral activity
(Fig. 5), also was the only mutant for which monomeric protein
was the only species detected (Fig. 6). While the other dimer in-
terfacemutant, F602D, also incurred a significant oligomerization
defect, faint lower-order oligomeric species still were detectable,
and this presumably was sufficient to support antiviral function
(Fig. 5). All other mutants tested exhibited an efficiency of lower-
oligomer formation comparable to that of wild-type MX1(NMX2)
(Fig. 6). Stalk interface 3 mutants and the L4 loop deletion exhib-
ited no or barely detectable higher-order oligomerization, in
agreement with a previous biochemical characterization of MX1
(10). The observation that these mutants, together with F602D,
retain full antiviral activity provides strong evidence that higher-
order oligomerization is not required for the inhibition of HIV-1
infection byMX1(NMX2). Stalk interface 1mutants and BSE hinge
mutants in the context of MX1(NMX2) incurred no observable
oligomerization defect in this assay.
Coimmunoprecipitation studies also were performed with
HA-tagged wild-typeMX1(NMX2) and FLAG-taggedMX1(NMX2)
stalk mutants, similar to those described for Fig. 4. Again, all HA-
tagged and FLAG-tagged constructs were well expressed in trans-
fected cells (Fig. 7, lower). As expected, FLAG-tagged wild-type
MX1(NMX2) failed to coprecipitate with the GFP-HA negative
control, but efficient coimmunoprecipitation was seen with the
HA-taggedwild-typeMX1(NMX2) positive control (Fig. 7, upper).
Robust coimmunoprecipitation also was observed between MX1
and MX1(NMX2). A far weaker interaction was observed between
MX2 and MX1(NMX2), but interestingly, the longer isoform of
MX1(NMX2) coprecipitated more efficiently than the short iso-
form, suggesting some role for theMX2N terminus in self-assembly
orprotein complex formation. In concordancewith the cross-linking
data, each of the MX1(NMX2) stalk and BSE hinge mutants tested
coprecipitated efficiently with wild-type MX1(NMX2), with the ex-
ception of the dimer interface mutants M527D and F602D. No de-
tectable interaction was observed with the short isoforms of either
mutant,while aweak interactionwasobservedwith the long isoform.
DISCUSSION
The ability to form structured higher-order oligomers is a com-
mon feature of dynamin-like GTPases (21), and, in the case of
humanMX1, higher-order oligomerization is critical for antiviral
FIG 5 Point mutation at the dimer interface abrogates anti-HIV-1 activity of
MX1(NMX2). (Upper) U87-MG CD4
 CXCR4 cells were transduced with
EasiLV vectors expressing FLAG-tagged CD8, MX1, MX2, and MX1(NMX2)
WT or a series of MX1(NMX2) variants with mutations at predicted stalk in-
terfaces 1, 2, and 3 and the BSE-hinge (H) region or with a deletion of the L4
loop (L4). After doxycycline treatment, cells were challenged with the HIV/
GFP lentiviral vector, and transduction efficiency was assessed as described in
the legend to Fig. 2. Mean percentages of transduced cells from three indepen-
dent experiments with standard deviations are shown. (Lower) Immunoblot
analysis of parallel samples from the upper panel. Levels of FLAG-tagged pro-
teins were determined, and Hsp90 was included as a loading control.
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activity against FLUAV (10). In the current study, we investigated
the importance of oligomerization for the antiviral activity of
MX2, a closely related family member and potent inhibitor of
HIV-1 infection (3–5). Previous biochemical characterization
of MX1 oligomerization (10, 16) and recent structural data ob-
tained for N-truncated MX2 (6) guided the construction of oli-
gomerization-defective mutant proteins in the context of both
MX2 and chimeric MX1(NMX2).
Our data demonstrate a clear requirement for the oligomeriza-
tion of MX2 for antiviral activity against HIV-1 (Table 2), in
agreement with previous reports (6, 31). Monomeric mutants
(defined here as oligomerization being undetectable by protein
cross-linking) all incurred a complete loss of antiviral activity (Fig.
2 and 3). These included M574D, Y651D, and F647D, all with
substitutions at the MX2 dimer interface. Our study also reveals a
relationship between the extent or efficiency of lower-order oli-
gomerization and the potency of antiviral activity. MX2 mutants
exhibiting reduced but still measurable lower-order oligomeriza-
tion by cross-linking, including V578D at the dimer interface,
R455D at stalk interface 3, and the L4 loop deletion mutant, all
displayed partial antiviral phenotypes. Although the coimmuno-
precipitation data broadly concurred with oligomerization phe-
notypes determined by cross-linking, efficient coimmunoprecipi-
tation was observed for some mutants with clearly reduced
antiviral activity, and a weak but detectable coimmunoprecipita-
FIG 6 Chemical cross-linking of MX1(NMX2) mutants. U87-MG CD4
 CXCR4 cells were transduced with EasiLV vectors expressing FLAG-tagged
MX1(NMX2)WT orMX1(NMX2) stalk mutants, and DSS cross-linking was performed as described in the legend to Fig. 3. FLAG-tagged protein was resolved by
SDS-PAGE and detected by immunoblotting. The HIV-1 inhibition phenotype of each mutant from Fig. 5 is indicated (calculated as percent inhibition relative
to that of the CD8 control);	,
50%;, 50 to 85%;,85%.
FIG 7 Coimmunoprecipitation of MX1(NMX2) stalk mutants with wild-type
MX1(NMX2). 293T cells were cotransfected with HA-tagged MX1(NMX2) WT
and FLAG-taggedMX1(NMX2)WT or stalkmutants. Immunoprecipitation of
HA-tagged protein with anti-HA antibody was performed as described in the
legend to Fig. 4. (Upper) Immunoblots of immunoprecipitated protein (IP)
were probed with anti-FLAG or anti-HA antibodies. (Lower) Immunoblots of
cell lysate prior to immunoprecipitation (INPUT) were probed with anti-
FLAG or anti-HA antibodies as a control for protein expression.
MX2 Oligomerization
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tion was noted with dimer interface mutants shown to be mono-
meric by cross-linking (Fig. 4). Since coimmunoprecipitation was
performed with cell lysates and is not dependent upon the prox-
imity of interacting proteins (the distance constraint for DSS pro-
tein cross-linking has been estimated to be 26 to 30 Å between
alpha carbon atoms of cross-linked lysine residues [32]), it is pos-
sible that some coimmunoprecipitation reflects the isolation of
MX protein-containing multiprotein complexes rather than direct
MX-MX interactions. Alternatively, the stability of interactions be-
tween wild-type andmutant proteins, when assessed by coimmuno-
precipitation,mayappeargreater than the stabilityofhomotypicmu-
tant protein interactions detected by protein cross-linking.
We observed no role for putative stalk interface 1 in either oli-
gomerizationorantiviral functionofMX2, arguingagainst its biolog-
ical relevance. Two previous studies, with the same M666D and
I423D mutants, also have concluded that this purported interface is
not required for antiviral activity (6, 31), although the lackof an effect
on oligomerization is in agreement with one study (31) but not the
other (6). The latter study was performed with recombinant, malt-
ose-binding protein (MBP)-tagged protein expressed in Escherichia
coli, which has the potential to behave differently than proteins
expressed in mammalian cells. However, since our study assessed
only single point mutants at interface 1, we cannot exclude the
possibility that themutations introduced here were insufficient to
disrupt the interface.
The HIV-1 inhibition phenotypes observed for stalk interface 3
mutants R455D and G439D and the L4 loop deletion were in agree-
ment with those observed previously (25), but here we show that
antiviral activity correlatedwith the relativeabilityof thesemutants to
form lower-order oligomers. Here, we also demonstrated a role for
the BSE hinge region in the antiviral activity of MX2, with mutants
E681A andR689Abeing significantly impaired forHIV-1 inhibition,
although a previous study found no effect of the E681Amutation on
function (6). The impact of these mutations on the oligomerization
ofMX2 had not been tested previously, but here we show by protein
cross-linking and coimmunoprecipitation that bothmutations incur
a moderate oligomerization defect that likely explains their func-
tional impairment.ThatmutantR689Aretainedanyantiviral activity
stands in contrast to corresponding mutant R640A in MX1, which
lost inhibitory function (16). Since the BSE hinge region has been
ascribed a role in conformational coupling between the GTPase do-
mainand the stalk, its lesser importance forMX2activitymayhavebeen
anticipated given theGTPase independence of this protein (3, 4).
Extending these studies, we also demonstrate the requirement
for lower-order oligomerization in the context of theMX1(NMX2)
chimera, implying that this attribute enables theMX2N-terminal
domain to mediate antiviral activity. Dimer interface mutant
M527D, which failed to form any detectable oligomeric species by
protein cross-linking, exhibited a complete loss of antiviral activ-
ity (Fig. 5 and 6). However,mutant F602D, which is alsomarkedly
defective for oligomerization but still showed very faint lower-
order cross-linking, was fully antiviral. PerhapsHIV-1 ismore sensi-
tive to inhibition by MX1(NMX2) than MX2, such that only a small
proportionof the active form is required. Indeed, theHIV-1 suppres-
TABLE 2 Oligomerization and HIV-1 inhibition data for MX2 and MX1(NMX2) mutants
a
Mutant Site
Inhibition
of HIV-1b
Oligomerization by
cross-linking Coimmunoprecipitation
MX2
WT  Higher order Yes
M666D Stalk 1  Higher order Yes
I423D Stalk 1  Higher order Yes
M574D Stalk 2  Monomeric Very weak
Y651D Stalk 2  Monomeric Very weak
V578D Stalk 2  Limited oligomerization Yes
F647D Stalk 2  Monomeric Very weak
E681A Hinge  Higher order Weak
R689A Hinge  Higher order Weak
YRGK-AAAA487–490 Stalk 3  Lower order Yes
R455D Stalk 3  Limited oligomerization Weak
G439D Stalk 3  Higher order Yes
L4 L4 loop  Lower order Yes
MX1(NMX2)
WT  Higher order Yes
L617D Stalk 1  Higher order Yes
I376D Stalk 1  Higher order Yes
M527D Stalk 2  Monomeric Weak
F602D Stalk 2  Limited oligomerization Weak
E632A Hinge  Higher order Yes
R640A Hinge  Higher order Yes
YRGR-AAAA440–443 Stalk 3  Higher order Yes
R408D Stalk 3  Lower order Yes
G392D Stalk 3  Lower order Yes
L4 L4 loop  Lower order Yes
a Summary of HIV-1 inhibition and protein oligomerization data shown in Fig. 2 to 7. The site, antiviral activity against HIV-1, oligomerization phenotype by protein cross-linking,
and coimmunoprecipitation efficiency with WT or mutant proteins described in this study are shown.
b The HIV-1 inhibition phenotype indicates percent inhibition calculated relative to that of the CD8 control (from Fig. 2 and 5):	, 0 to 50%;, 50 to 85%;, 85 to 100%.
Mutants exhibiting a complete loss of antiviral activity are highlighted in boldface.
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sion phenotype observed upon the expression of MX1(NMX2) typi-
cally is stronger than that forMX2 (23).
The data presented here corroborate previous observations us-
ing constructs in which the amino-terminal 91 residues of MX2
were fused to monomeric, dimeric, or trimeric versions of the
yeast GCN4 leucine zipper domain (20). Dimeric and trimeric
constructs retained80% antiviral activity, while themonomeric
construct was not antiviral, implying that the dimerization of the
MX2 N terminus is sufficient for antiviral activity to be elicited
(20). Extending this observation, we now conclude that higher-
order oligomerization is dispensable for full antiviral activity, par-
ticularly in the context of MX1(NMX2). Dimer interface mutant
F602D, stalk interface 3 mutants R408D, G392D, and YRGR440-
AAAA443, and the L4 loop deletion all exhibited no (or barely)
detectable higher-order oligomerization yet retained full antiviral
activity in this context. The dependence of MX2 activity upon
dimerization is reminiscent of fusions between the murine leuke-
mia virus restriction factor Fv1 and cyclophilin A; these chimeric
proteins also suppress infectionby inhibiting viral cDNAnuclear im-
port, perhaps indicating commonalities in mechanism (33, 34).
Notably, wild-type MX2 and MX1(NMX2) both exhibited pro-
files of lower-order and higher-order oligomeric forms by cross-
linking that were similar to those ofMX1 (Fig. 3A). However, and
despite the similarities in structure and propensity to formhigher-
order oligomers, current data support the conclusion that there
are a number of fundamental differences between the antiviral
mechanisms of MX1 and MX2.
The mechanism underpinning the requirement for MX2 oli-
gomerization is not presently understood. Previous studies have
shown that monomeric MX2 mutants fail to bind HIV-1 capsid-
nucleocapsid nanotubes in vitro (6, 31). However, further inves-
tigation is required to determine the precise nature and relevance
of the interaction between MX2 and CA, since mutations in CA
that permit viral escape from MX2-mediated inhibition do not
block MX2 binding in vitro (7, 8). The potential involvement of
additional cellular factors, as well as the importance of MX2 oli-
gomerization for their recruitment, will require future exploration.
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